Abstract
De novo oligometastatic breast cancer (OMBC) is a rare presentation of advanced stage breast cancer (BC) with ≤ 5 metastatic lesions at diagnosis. Its clinical management is not well defined because of varying definitions, lack of specific biomarkers and lack of dedicated prospective clinical studies. Here, we investigated tumor immune microenvironment, classical clinic-pathological parameters including treatment and correlated them with survival in a cohort of de novo OMBC patients to better characterize this disease entity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
